← Eichor
Condition: Primary Immune Thrombocytopenic Purpura Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Primary Immune Thrombocytopenic Purpura

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)
Phase 1 · 5 location(s) · Chongqing Peg-Bio Biopharm Co., Ltd. · NCT06880081Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults
Phase 4 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT04518475Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Th
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07206823A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Phase 1/Phase 2 · 45 location(s) · Eli Lilly and Company · NCT06721013The Efficacy and Safety of HCQ Plus DEX in ANA Positive ITP
NA · 7 location(s) · Yunfeng Cheng · NCT06479317Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thromb
Phase 3 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05338190An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06799611Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)
Phase 1/Phase 2 · 1 location(s) · 920th Hospital of Joint Logistics Support Force of People's · NCT06352281High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patien
Phase 3 · 1 location(s) · Shandong University · NCT07559331A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05995054A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytop
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06094881A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia
Phase 1/Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06776510Study on Glucocorticoid Combined With Gamma Globulin and Ropristine N01 in Treatment of Initial Severe ITP
Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06686927Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (w
Phase 2 · 25 location(s) · Novartis Pharmaceuticals · NCT07039422A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Phase 3 · 109 location(s) · Takeda · NCT06948318The Efficacy and Safety of HCQ Plus Pred in ANA Positive ITP
NA · 7 location(s) · Yunfeng Cheng · NCT06479304A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With
Phase 1/Phase 2 · 7 location(s) · Jiangsu BioJeTay Biotechnology Co., Ltd. · NCT06929299Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
Phase N/A · 1 location(s) · Institut National de la Santé Et de la Recherche Médicale, F · NCT04902807A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
Phase 3 · 94 location(s) · argenx · NCT06544499A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC
Phase 2 · 5 location(s) · Novartis Pharmaceuticals · NCT07421167An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia
EARLY_Phase 1 · 1 location(s) · Changzhou No.2 People's Hospital · NCT06337474Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07063199The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP
NA · 7 location(s) · Yunfeng Cheng · NCT06479291A Study of Romiplostim N01 as the First-line Treatment for Newly Diagnosed Adult Patients With ITP
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06658834Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07297563A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06838949RESTI Registry: Spanish Registry of Primary Immune Thrombocytopenia and Other Immune Thrombocytopenia
Phase N/A · 36 location(s) · Fundación Española de Hematología y Hemoterapía · NCT06919341An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia
Phase 3 · 9 location(s) · Grand Shuyang Life Sciences (Chengdu) Co., Ltd. · NCT07233213Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07234019Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia
Phase 1 · 1 location(s) · Guangdong Hengrui Pharmaceutical Co., Ltd · NCT07206758
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.